Outlook Wealth Advisors LLC Grows Position in Zoetis Inc. (NYSE:ZTS)

Outlook Wealth Advisors LLC grew its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 66.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,371 shares of the company's stock after purchasing an additional 2,153 shares during the quarter. Outlook Wealth Advisors LLC's holdings in Zoetis were worth $875,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Cherry Creek Investment Advisors Inc. lifted its stake in Zoetis by 2.0% in the third quarter. Cherry Creek Investment Advisors Inc. now owns 3,021 shares of the company's stock valued at $590,000 after buying an additional 58 shares during the period. Grove Bank & Trust boosted its holdings in Zoetis by 0.5% during the third quarter. Grove Bank & Trust now owns 11,763 shares of the company's stock worth $2,298,000 after purchasing an additional 61 shares during the last quarter. Hancock Whitney Corp increased its position in shares of Zoetis by 0.3% during the third quarter. Hancock Whitney Corp now owns 18,569 shares of the company's stock valued at $3,628,000 after acquiring an additional 61 shares during the last quarter. Strategy Asset Managers LLC grew its stake in Zoetis by 3.5% in the 3rd quarter. Strategy Asset Managers LLC now owns 1,822 shares of the company's stock valued at $356,000 after purchasing an additional 62 shares during the period. Finally, Edge Capital Group LLC boosted its stake in Zoetis by 3.7% in the second quarter. Edge Capital Group LLC now owns 1,786 shares of the company's stock valued at $310,000 after acquiring an additional 64 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the company. Leerink Partners initiated coverage on Zoetis in a research note on Monday, December 2nd. They issued an "outperform" rating and a $215.00 price objective on the stock. Leerink Partnrs raised shares of Zoetis to a "strong-buy" rating in a report on Monday, December 2nd. UBS Group initiated coverage on shares of Zoetis in a research note on Monday, December 9th. They issued a "neutral" rating and a $196.00 target price on the stock. JPMorgan Chase & Co. raised their price objective on Zoetis from $225.00 to $230.00 and gave the company an "overweight" rating in a report on Friday, October 11th. Finally, Stifel Nicolaus reduced their price objective on Zoetis from $210.00 to $180.00 and set a "buy" rating on the stock in a research note on Tuesday, January 7th. One investment analyst has rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $211.89.

Zoetis Trading Up 1.4 %

Shares of NYSE:ZTS traded up $2.31 on Thursday, hitting $169.48. The company had a trading volume of 1,953,175 shares, compared to its average volume of 2,594,107. The firm's 50-day simple moving average is $171.31 and its two-hundred day simple moving average is $180.16. The firm has a market capitalization of $76.47 billion, a price-to-earnings ratio of 31.87, a P/E/G ratio of 2.51 and a beta of 0.89. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $200.53.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business had revenue of $2.40 billion for the quarter, compared to analysts' expectations of $2.29 billion. During the same period in the previous year, the firm posted $1.36 EPS. The business's revenue was up 11.6% on a year-over-year basis. Equities analysts anticipate that Zoetis Inc. will post 5.91 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, January 21st will be paid a dividend of $0.50 per share. The ex-dividend date is Tuesday, January 21st. This represents a $2.00 annualized dividend and a yield of 1.18%. This is a positive change from Zoetis's previous quarterly dividend of $0.43. Zoetis's payout ratio is presently 32.52%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.